In medical terms, a “quadruplet” refers to a combination of four medications. It means four medications working on the cancer from four different directions at once, starting on day one.
Induction therapy is the opening phase of multiple myeloma treatment, the stretch of months designed to knock down the disease as quickly and as deeply as possible. For years, the standard first myeloma treatment combined three drugs. The field has since moved toward adding a fourth, making quadruplet induction the standard front-line approach for newly diagnosed multiple myeloma treatment.
The goal behind that shift is depth of response. Clinicians are looking for minimal residual disease (MRD) negativity, meaning no myeloma cells can be detected even with highly sensitive testing. Induction sets the stage for everything that follows, whether that’s consolidation, a stem cell transplant, or maintenance.
Understanding the quadruplet. How the four components work
Each drug class attacks the disease differently. Understanding what a myeloma cell is helps here. It’s an abnormal plasma cell in your bone marrow that multiplies and crowds out healthy blood production.
- CD38 monoclonal antibodies latch onto the CD38 protein sitting on the surface of myeloma cells, flagging them for destruction by your immune system. This is the “fourth” drug in most quadruplet regimens.
- Proteasome inhibitors (PIs) block the cell’s protein-recycling machinery. Myeloma cells produce enormous amounts of protein, so when the disposal system jams, they die.
- Immunomodulatory drugs (IMiDs) reactivate immune cells to recognize and attack the cancer.
- Corticosteroids like dexamethasone are an important part of multiple myeloma treatment and are often combined with other drugs as part of quadruplet induction therapy.
Common regimens and administration logistics
The most familiar quadruplet regimen is D-VRd for multiple myeloma: daratumumab, bortezomib, lenalidomide, and dexamethasone. Isa-VRd, which substitutes isatuximab, follows the same architecture, as does D-VTd, which uses thalidomide in place of lenalidomide.
Administration varies by drug. Daratumumab can be given as a subcutaneous injection under the skin or as an intravenous (IV) infusion. Bortezomib is typically a subcutaneous injection. Lenalidomide and dexamethasone are oral pills you take at home.
Most of this happens in an outpatient infusion center, you arrive, receive treatment, and go home the same day. Standard multiple myeloma induction therapy is typically given on an outpatient basis and does not require hospitalization, though hospitalization may be needed in certain circumstances such as stem cell transplantation.
The treatment timeline: rounds and duration
A common question early on is. How long does myeloma induction therapy last?
Induction is measured in cycles, not weeks. A cycle is usually 21 or 28 days and includes treatment days followed by a built-in rest period that lets your blood counts recover. Four to six cycles is a common induction course, which works out to roughly four to six months of quadruplet regimen myeloma treatment before the next phase begins.
Within each cycle, your schedule shifts. Daratumumab is often given weekly at first, then spaced out to every other week, then monthly. Bortezomib follows its own weekly rhythm. Lenalidomide is taken for a set stretch of days, then paused.
Throughout, your care team tracks response with blood and urine tests, monitoring M-protein, free light chains, kidney function, and blood counts. Those numbers tell your oncologist whether the quadruplet is working and whether any dose needs adjusting.
Determining if induction is the right first step
One of the first decisions your care team makes is whether you’re a candidate for multiple myeloma treatment before stem cell transplant. Transplant eligibility depends less on age alone than on organ function, fitness, and other medical conditions. Transplant-eligible patients typically receive quadruplet induction before stem cell transplant, with stem cells collected after a few cycles.
Cytogenetic testing, often FISH testing on a bone marrow sample, identifies chromosomal abnormalities that define standard-risk versus high-risk disease. That result can influence drug selection, cycle count, and what follows induction.
Because these decisions compound, an early consultation with a myeloma specialist is worth pursuing. A personalized care plan built at diagnosis is far easier than course-correcting later.
Managing side effects and treatment limitations
Side effects of quadruplet myeloma treatment are significant, and understanding what to expect can make them easier to manage.
Fatigue is a common side effect that many patients experience during quadruplet myeloma treatment, though its severity and timing can vary from person to person. Peripheral neuropathy, tingling, numbness, or burning in the hands and feet, is associated with proteasome inhibitors and should be reported early. Early recognition and treatment of peripheral neuropathy, including dose adjustments when needed, can help make neuropathy reversible in many myeloma patients. Infection risk rises because both the disease and the drugs suppress immune function, so fevers warrant a same-day call to your care team.
Dexamethasone deserves its own mention. Many people feel wired and sleepless on steroid days, then crash into exhaustion and low mood a day or two later. Scheduling demanding tasks around that pattern helps.
Quadruplet and triplet myeloma treatments involve different approaches to induction therapy. Your care team can discuss with you how the potential benefits and side effects of each option may apply to your individual situation.
When quadruplet therapy might not be recommended
A four-drug regimen isn’t automatically better for everyone. Your overall health and other medical conditions you may have are important factors your care team will consider when choosing which quadruplet regimen is right for you.
Frailty assessment matters more than chronological age. A formal evaluation of mobility, comorbidities, and daily functioning may suggest a triplet or even a doublet regimen that preserves function while still controlling the disease.
Logistics count too. Weekly infusion visits during the first cycles require transportation, time away from work, and often a caregiver. When that burden can’t be sustained, a less frequent regimen followed consistently may serve you better than an intensive one you can’t complete.
Common questions about myeloma induction
What is the most promising treatment for multiple myeloma? For frontline treatment of multiple myeloma, daratumumab-based quadruplet therapy represents the current direction of the field. CAR-T cell therapy and bispecific antibodies, both forms of immunotherapy, are reshaping options for relapsed disease, and trials are testing whether they belong earlier in treatment.
Does induction therapy cure myeloma? Myeloma is considered treatable but not generally curable. What induction can achieve is a deep, durable remission, including MRD negativity, that may last years. That distinction matters, and your care team should discuss it plainly with you.
Can I work during quadruplet induction? Many people do, particularly with flexible or remote arrangements. Expect the first cycles to be the most demanding, with frequent appointments and the steepest fatigue. Talking with your employer early about schedule flexibility tends to be more effective than improvising month to month.
Key takeaways
Understanding what multiple myeloma is and how induction fits into the larger treatment plan gives you footing at a moment when very little feels stable.
- Quadruplet induction is the current front-line standard. Four drugs, a CD38 antibody, a proteasome inhibitor, an immunomodulatory drug, and a corticosteroid, work together to reduce myeloma cells as deeply as possible from the start.
- Induction typically runs four to six cycles, each 21 or 28 days, totaling roughly four to six months before transplant or the next phase of care.
- Your regimen is personalized. Transplant eligibility, cytogenetic risk, kidney and heart function, and frailty all shape which drugs you receive and at what doses.
- Reporting side effects early protects your schedule. Neuropathy, infection, and fatigue are manageable when addressed promptly, and staying on treatment is what drives response.
- Ask about MRD testing and what your results mean for the phase that follows induction.
Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.
